About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease

TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of T cell receptor (TCR)-based T cell therapies for the treatment of cancer. Shares of the T cell biopharma company are soaring 121% through early trading on Tuesday, May 9, 2023. Over the past three months, TScan Therapeutics has seen an average daily volume of 40,100 shares. However, a volume of 22 million shares or dollar volume of around $117.04 million, has already exchanged hands through early trading.

Shares of TScan Therapeutics are skyrocketing after Amgen (NASDAQ: AMGN) and TScan Therapeutics have announced a multi-year collaboration to identify antigens recognized by T cells in patients with Crohn’s disease. The partnership will leverage TScan’s proprietary target discovery platform, TargetScan, to find these antigens. The agreement stipulates that TScan will receive an upfront payment of $30 million and could potentially earn over $500 million in success-based milestones spanning preclinical, clinical, regulatory, and commercial stages. Furthermore, TScan is eligible for tiered single-digit royalty payments.

Amgen, a leading biopharmaceutical company, will take on the responsibility of developing therapeutics based on the targets identified by TScan. It will retain all global development and commercial rights to these potential treatments. The collaboration could potentially be expanded to cover ulcerative colitis, another inflammatory bowel disease, under certain conditions. Each company will fund its own research expenses.

This collaboration aims to advance treatments for inflammatory bowel diseases (IBD), a term that encompasses both Crohn’s disease and ulcerative colitis. These conditions are characterized by chronic inflammation of the gastrointestinal tract. The current standard of care mainly involves anti-inflammatory drugs, which often lack efficacy and durability, according to Raymond Deshaies, senior vice president of Global Research at Amgen. TScan’s platform, as per Gavin MacBeath, acting CEO and CSO at TScan, is specifically designed to identify antigens targeted by the immune system in IBD, thereby potentially enabling the development of first-in-class therapeutics to address these unmet medical needs.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.